



SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093
Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, CIN : L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER, 2016

S. No.	Particulars (Rs. in lacs)	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2016 (Unaudited)	30.09.2016 (Unaudited)	31.12.2015 (Unaudited)	31.12.2016 (Unaudited)	31.12.2015 (Unaudited)	31.03.2016 (Audited)
01	(a) Net Income From Operations	4489.69	4676.69	4548.96	13448.99	13459.12	18190.48
	(b) Other Operating Income	49.69	41.83	39.56	158.29	144.82	199.22
	Total Income from Operation	4539.38	4718.52	4588.52	13607.28	13603.94	18389.70
02	Expenses						
	(a) Cost of Materials consumed	1796.62	1669.17	1623.47	5126.74	6070.64	6890.03
	(b) Purchase of stock in trade	1359.81	1879.09	1860.81	4086.94	3675.11	6630.17
	(c) Changes in inventories	(24.45)	(190.51)	(145.04)	267.77	(82.54)	(365.04)
	(d) Employee benefits expenses	330.06	301.09	335.33	991.60	985.59	1361.37
	(e) Depreciation and amortization expenses	80.00	85.00	84.00	250.00	255.00	299.81
	(f) Other expenses	582.89	622.18	463.09	1817.51	1618.95	2212.82
	Total Expenses	4124.93	4366.02	4221.66	12540.56	12522.75	17029.16
03	Profit/(Loss) from Operations before other (1-2) income, finance costs and exceptional items	414.45	352.50	366.86	1066.72	1081.19	1360.54
04	Other Income	58.74	86.67	98.04	230.53	164.48	266.83
05	Profit/(Loss) from Ordinary activities before finance costs and exceptional items (3-4)	473.19	439.17	464.90	1297.25	1245.67	1627.37
06	Interest & Financial Charges	7.48	6.77	1.90	21.15	5.00	7.09
07	Operating Profit after interest & exceptional items(5-6)	465.71	432.40	463.00	1276.10	1240.67	1620.28
08	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
09	Profit/(Loss) from Ordinary activities before tax	465.71	432.40	463.00	1276.10	1240.67	1620.28
10	Tax expenses	185.00	135.00	198.00	445.00	430.30	574.53
11	Net Profit/(+)/Loss(-) from ordinary activities after tax(9-10)	280.71	297.40	265.00	831.10	810.37	1045.75
12	Extraordinary items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	10.19
13	Net Profit/(+)/Loss(-) for the period (11-+12)	280.71	297.40	265.00	831.10	810.37	1035.56
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority interest	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit/(Loss) after taxes, minority interest & share of profit/loss of associates (13+14+15)	280.71	297.40	265.00	831.10	810.37	1035.56
17	Paid-up equity Share Capital (Equity share of Rs. 1 each)	7806.52	7806.52	7806.52	7806.52	7806.52	7806.52
18	Reserves (excluding Revaluation Reserves)	0.00	0.00	0.00	0.00	0.00	3063.44
19	(I) Earning Per Share (EPS) before extraordinary items (in 1/- each) (not annualised)						
	a) Basic Earning per share	0.04	0.04	0.03	0.11	0.10	0.13
	b) Diluted Earning Per Share	0.04	0.04	0.03	0.11	0.10	0.13
19	(II) Earning Per Share (EPS) (after extraordinary items (in 1/- each) (not annualised)						
	a) Basic Earning per share	0.04	0.04	0.03	0.11	0.10	0.13
	b) Diluted Earning Per Share	0.04	0.04	0.03	0.11	0.10	0.13

SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS

S. No.	Particulars (Rs. in lacs)	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2016 (Unaudited)	30.09.2016 (Unaudited)	31.12.2015 (Unaudited)	31.12.2016 (Unaudited)	31.12.2015 (Unaudited)	31.03.2016 (Audited)
1	Segment Revenue						
	(a) Pharmaceuticals Drugs & Formulations	3750.84	3893.38	4626.71	11656.13	12040.06	16862.50
	(b) Trading of Commodities	804.76	836.42	35.30	1997.18	1673.18	1713.42
	(c) Renting of Property	42.52	75.40	24.55	184.50	55.18	80.61
	Total	4598.12	4805.20	4686.56	13837.81	13768.42	18656.53
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Net Sales/Income from Operations	4598.12	4805.20	4686.56	13837.81	13768.42	18656.53
2	Segment Results (Profit)/Loss(-) before tax and interest from each Segment						
	(a) Pharmaceuticals Drugs & Formulations	320.10	238.52	497.35	871.58	1114.69	1463.91
	(b) Trading of Commodities	110.57	125.25	3.01	241.17	75.80	82.84
	(c) Renting of Property	42.52	75.40	24.55	184.50	55.18	80.61
	Total	473.19	439.17	464.90	1297.25	1245.67	1627.36
	Less: (i) Interest	7.48	6.77	1.90	21.15	5.00	7.09
	(ii) Other Un-allocable Expenditure net off	0.00	0.00	0.00	0.00	0.00	0.00
	(iii) Un-allocable Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Profit Before Tax	465.71	432.40	463.00	1276.10	1240.67	1620.28
3	Capital Employed (Segment Assets - Segment Liabilities)						
	(a) Pharmaceuticals Drugs & Formulations	9362.59	8025.80	10429.36	9362.59	10429.36	8692.60
	(b) Trading of Commodities	101.67	231.40	22.03	101.67	22.03	113.29
	(c) Renting of Property	3013.50	3943.84	991.84	3013.50	991.84	2690.78
	(d) Unallocated	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed	12477.77	12201.04	11443.23	12477.77	11443.23	11496.66

Notes:

- The above standalone Unaudited Financial Results were approved by the Audit Committee and the Board of Directors at their meetings held on 13th February 2017.
- The limited review under regulation 33 of the SEBI (LODR) Regulations, 2015 has been carried out by the Statutory Auditors. The report does not contain anything which would have an impact on the results for the Quarter ended 31st December 2016.
- The company is operating in three segment i.e.: (a)Pharmaceutical Drugs & Formulations, (b) Trading of commodities and (c) Renting of Property, particulars for segment wise results enclosed herewith.
- Figures for the previous periods/year have been regrouped wherever necessary.
- The Company is having one wholly owned foreign subsidiary viz Trade Services FZE in RAK Investment Authority, Ras Al Khaimah emirate of the United Arab Emirates, which has not commenced any business so far and is exploring any further business opportunities, the Board of directors of the company at their Meeting decided to close/liquidate the same in necessary steps in this regards as per applicable law.

Place : Indore
Dated : 13/02/2017

